A high eosinophil proportion increases the risk of skin-related adverse events induced by apalutamide in patients with prostate cancer.

Abstract

Background: Skin-related adverse events (AEs) induced by apalutamide occur frequently in Japanese patients with prostate cancer. However, biomarkers for predicting these skin-related AEs have not yet been identified. Therefore, this study investigated whether the proportion of eosinophils could serve as a predictive biomarker for skin-related AEs in Japanese patients with prostate cancer treated with apalutamide.

Methods: A total of 109 patients were enrolled in this study. Among them, 79 patients with prostate cancer who received apalutamide were categorized into two groups: the skin AE group (n = 45) and the non-skin AE group (n = 34), based on whether they experienced skin-related AEs of any grade. The eosinophil proportions in baseline samples collected before treatment were then analyzed.

Results: The baseline eosinophil proportion was significantly higher in the skin AE group compared with the non-skin AE group (P < 0.05). The optimal cut-off value of the eosinophil proportion for predicting skin-related AEs of any grade was 1.8% (area under the receiver operating characteristic curve [AUC] = 0.768). In multivariate analysis, an eosinophil proportion ≥1.8% was identified as an independent factor associated with skin-related AEs of any grade (odds ratio, 13.3; 95% confidence interval, 3.82-46.4; P < 0.05).

Conclusion: The baseline eosinophil proportion may serve as a predictive biomarker for skin-related AEs of any grade in Japanese patients with prostate cancer treated with apalutamide.